Ani Pharmaceuticals (ANIP) Inventory (2012 - 2026)

Ani Pharmaceuticals has disclosed Inventory across 15 years of filings, most recently posting $143.5 million for Q1 2026.

• Inventory for Q1 2026 came in at $143.5 million, up 4.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $143.5 million (up 4.41% YoY), and the FY2025 annual result was $143.1 million, up 4.59% from the prior year.
• Inventory came in at $143.5 million for Q1 2026 at Ani Pharmaceuticals, roughly flat from $143.1 million in the prior quarter.
• In the past five years, Inventory ranged from a high of $148.0 million in Q3 2024 to a low of $83.2 million in Q1 2022.
• The 5-year median for Inventory is $113.8 million (2024), against an average of $120.8 million.
• Across the five-year window, Inventory surged 70.75% in 2022 and dropped 1.06% in 2025, its largest moves.
• Ani Pharmaceuticals' Inventory stood at $105.4 million in 2022, then gained by 5.54% to $111.2 million in 2023, then advanced by 23.01% to $136.8 million in 2024, then climbed by 4.59% to $143.1 million in 2025, then climbed by 0.28% to $143.5 million in 2026.
• The last three Inventory figures came in at $143.5 million (Q1 2026), $143.1 million (Q4 2025), and $146.5 million (Q3 2025), per Business Quant data.